Modulation of Inflammation in Periodontal Disease

Periodontitis is one of the most prevalent chronic inflammatory diseases affecting adults worldwide, with substantial economic and systemic health implications. It arises from a dysbiotic biofilm that triggers a host immune response, leading to connective tissue breakdown and alveolar bone resorption. Traditional mechanical therapies, such as scaling and root planing, address the microbial component but often fail to fully resolve inflammation or promote tissue regeneration. Consequently, modulation of the host inflammatory response has emerged as a complementary strategy. By rebalancing pro- and anti-inflammatory mediators, enhancing epithelial barrier function and guiding microbial communities towards homeostasis, these approaches aim to limit tissue damage, foster wound healing and improve long-term outcomes both locally and across systemic health domains.

Research from Nature Portfolio

Investigations have illuminated the role of fatty acid metabolites in preserving gingival barrier integrity. One foundational study showed that a microbial-derived hydroxy fatty acid activates a GPR40 receptor on gingival epithelial cells, preventing the degradation of adhesion proteins and attenuating cytokine release in response to periodontopathic challenges. This work highlights barrier preservation as a novel anti-inflammatory tactic. A systematic review and meta-analysis of systemic host modulators as adjuncts to non-surgical therapy assessed agents such as sub-antimicrobial-dose doxycycline, melatonin and a combined regimen of omega-3 fatty acids with low-dose aspirin. Findings indicated improved pocket depth reduction and clinical attachment gains in specific patient groups, underscoring the importance of optimising dosage, timing and patient selection to maximise therapeutic benefit.

Modulation of Inflammation in Periodontal Disease publication trend

The graph below shows the total number of articles in modulation of inflammation in periodontal disease across all publications each year (not limited to Nature Index journals).

Technical terms

Specialized pro-resolving mediators (SPMs): Endogenous lipid compounds derived from omega-3 fatty acids that orchestrate the active resolution of inflammation and promote tissue repair.

Host modulation therapy: Therapeutic approach targeting the patient’s immune and inflammatory pathways to reduce tissue destruction and enhance healing in periodontal disease.

GPR40 receptor: A G-protein coupled receptor on epithelial cells that senses long-chain fatty acids and modulates barrier function and inflammatory signalling.

Non-steroidal anti-inflammatory drugs (NSAIDs): A class of medications that inhibit cyclooxygenase enzymes to alleviate pain, reduce inflammation and affect platelet function.

References

1. The role of non-steroidal anti-inflammatory drugs as adjuncts to periodontal treatment and in periodontal regeneration. Journal of Translational Medicine (2023).
2. The association between polyunsaturated fatty acids and periodontitis: NHANES 2011–2014 and Mendelian randomisation analysis. Lipids in Health and Disease (2024).
3. Roles of specialized pro-resolving mediators and omega-3 polyunsaturated fatty acids in periodontal inflammation and impact on oral microbiota. Frontiers in Oral Health (2023).
4. A bacterial metabolite ameliorates periodontal pathogen-induced gingival epithelial barrier disruption via GPR40 signaling. Scientific Reports (2018).
5. Systematic review and meta-analysis on the adjunctive use of host immune modulators in non-surgical periodontal treatment in healthy and systemically compromised patients. Scientific Reports (2021).